Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,069 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Cohort 3 Clear all

Conditions: Healthy
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alport Syndrome
Interventions: Placebo Oral Capsule, Bardoxolone Methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Sjögren Syndrome
Interventions: CFZ533, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more

Conditions: Keloid
Interventions: STP705, Placebo; Drug · Other
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey

Conditions: Tuberculosis
Interventions: PNU-100480, Placebo; Drug
Lead sponsor: Sequella, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: TAK-988, TAK-988 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Glendale, California • Millcreek, Utah

Conditions: Safety, Pharmacokinetics, Pharmacodynamics
Interventions: Kratom, Placebo; Drug
Lead sponsor: Altasciences Company Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity and Overweight
Interventions: NNC0165-1875, Placebo (NNC0165-1875), Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obese, Overweight, Healthy
Interventions: LB64640, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy
Interventions: P7435, Placebo; Drug · Other
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Dementia, Alzheimer's Disease
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 14
States / cities: Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more

Conditions: Acromegaly
Interventions: MAR002, Placebo; Drug
Lead sponsor: Marea Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Genital Warts
Interventions: GS-9191 ointment, GS-9191, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more

Conditions: Asthma in Children
Interventions: Inulin; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Chronic HBV Infection
Interventions: EDP-514, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 11
States / cities: Coronado, California • Los Angeles, California • San Diego, California + 8 more

Conditions: Digestive System Disease
Interventions: PvP001 placebo, PvP001 100 mg, PvP001 300 mg, PvP001 900 mg, Maximum Feasible Dose (MFD) of PvP002, Maximum Tolerated Dose (MTD) of PvP001, MTD of PvP001 following 7 days of PPI treatment, PvP002 placebo, PvP001 600 mg, PvP003 placebo, PvP003, PvP003 150 mg; Other · Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Traumatic Brain Injury
Interventions: SLV334, Placebo; Drug
Lead sponsor: Abbott Products; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Baltimore, Maryland • Dayton, Ohio • Portland, Oregon + 1 more

Conditions: Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells); Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: SKL24741, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Scleroderma, Systemic
Interventions: GSK2330811, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more

Search by objective public record fields.

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Study of MAR002 in Healthy Men

Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

A Clinical Trial of Soluble Fiber for Asthma

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis